Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.72 USD
Change Today -0.0201 / -2.72%
Volume 564.4K
RXII On Other Exchanges
As of 1:56 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

rxi pharmaceuticals (RXII) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/2/14 - $4.44
52 Week Low
03/31/15 - $0.69
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RXI PHARMACEUTICALS (RXII)

Related News

No related news articles were found.

rxi pharmaceuticals (RXII) Related Businessweek News

No Related Businessweek News Found

rxi pharmaceuticals (RXII) Details

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company’s lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages include products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

12 Employees
Last Reported Date: 03/28/14
Founded in 2011

rxi pharmaceuticals (RXII) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $368.1K
Chief Development Officer
Total Annual Compensation: $324.4K
Compensation as of Fiscal Year 2013.

rxi pharmaceuticals (RXII) Key Developments

RXi Pharmaceuticals Corporation and MirImmune LLC Enter into an Exclusive License Agreement

RXi Pharmaceuticals Corporation and MirImmune LLC announced that they have entered into an exclusive license agreement to RXi's novel and proprietary sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration has the potential to result in novel, more effective and patient friendly cancer treatments that could be a significant step toward personalised medicine. Under the terms of the agreement, MirImmune will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. It will develop cell-based therapeutics utilizing the company's sd-rxRNA technology to target immune inhibitory pathways (checkpoints) which are responsible for limiting the efficacy of cancer immunotherapies. According to the terms, MirImmune will gain access to the company's sd-rxRNA and rxRNAori patent families for ex vivo modification of cells for the treatment of cancer. These patents include the composition of the sd-rxRNA and rxRNAori RNAi structures, as well as potential targets for cell-based therapeutics.

RXi Pharmaceuticals Corporation to Report Q4, 2014 Results on Mar 30, 2015

RXi Pharmaceuticals Corporation announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 30, 2015

RXi Pharmaceuticals Corporation, Q4 2014 Earnings Call, Mar 30, 2015

RXi Pharmaceuticals Corporation, Q4 2014 Earnings Call, Mar 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXII:US $0.72 USD -0.0201

RXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXII.
View Industry Companies

Industry Analysis


Industry Average

Valuation RXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 150.5x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RXI PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at